Forum.
- Published in:
- Pharmaceutical Medicine, 2020, v. 34, n. 6, p. 407, doi. 10.1007/s40290-020-00368-3
- Publication type:
- Article
Works matching IS 11782595 AND DT 2020 AND VI 34 AND IP 6
Results: 8
1
2
The Unintended Consequences of Adverse Event Information on Medicines' Risks and Label Content.
- Published in:
- Pharmaceutical Medicine, 2020, v. 34, n. 6, p. 369, doi. 10.1007/s40290-020-00367-4
- By:
- Publication type:
- Article
3
Major Pharmaceutical Conferences and Courses: February to March 2021.
- Published in:
- Pharmaceutical Medicine, 2020, v. 34, n. 6, p. 415, doi. 10.1007/s40290-020-00366-5
- Publication type:
- Article
4
Acknowledgement to Referees.
- Published in:
- Pharmaceutical Medicine, 2020, v. 34, n. 6, p. 363, doi. 10.1007/s40290-020-00365-6
- Publication type:
- Article
5
Current Challenges in Labelling for Generic Medicinal Products: Company Core Data Sheet (CCDS) Development and Maintenance.
- Published in:
- Pharmaceutical Medicine, 2020, v. 34, n. 6, p. 381, doi. 10.1007/s40290-020-00364-7
- By:
- Publication type:
- Article
6
The Pharmaceutical Year That Was, 2020.
- Published in:
- 2020
- By:
- Publication type:
- Editorial
7
Risk Minimisation Evaluation with Process Indicators and Behavioural or Health Outcomes in Europe: Systematic Review.
- Published in:
- Pharmaceutical Medicine, 2020, v. 34, n. 6, p. 387, doi. 10.1007/s40290-020-00361-w
- By:
- Publication type:
- Article
8
Plain Language Summaries of Clinical Trial Results: A Preliminary Study to Assess Availability of Easy-to-Understand Summaries and Approaches to Improving Public Engagement.
- Published in:
- Pharmaceutical Medicine, 2020, v. 34, n. 6, p. 401, doi. 10.1007/s40290-020-00359-4
- By:
- Publication type:
- Article